Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol

Eur J Med Chem. 2019 Feb 1:163:1-9. doi: 10.1016/j.ejmech.2018.11.042. Epub 2018 Nov 22.

Abstract

VEGFR-2, Tie-2, and EphB4 are essential for both angiogenesis and tumorigenesis. Herein, we developed a series of pyridines incorporated with 1,2,3-triazole as multi-target inhibitors based on the crystal structure alignment of the kinase domain of angiogenic RTKs. Biological results indicated that these multi-target inhibitors displayed considerable potential as novel anti-angiogenic agents. Among them, compound BD7 exhibited the most potent inhibition against the three RTKs simultaneously, and good activity on inhibiting viability of human umbilical endothelial cells. Therefore, 1,2,3-triazole could serve as a promising DFG binding group for multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 bearing pyridine as hinge binding group.

Keywords: 1,2,3-Triazole; Anti-angiogenic agents; DFG-binding group; Multi-target; Triple RTK inhibitors.

MeSH terms

  • Angiogenesis Inhibitors / chemical synthesis*
  • Angiogenesis Inhibitors / pharmacology
  • Cell Survival / drug effects
  • Drug Discovery
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Protein Kinases
  • Pyridines / chemistry*
  • Receptor, EphB4 / antagonists & inhibitors*
  • Receptor, TIE-2 / antagonists & inhibitors*
  • Triazoles / chemistry*
  • Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Pyridines
  • Triazoles
  • Protein Kinases
  • Receptor, EphB4
  • Receptor, TIE-2
  • TEK protein, human
  • Vascular Endothelial Growth Factor Receptor-2